The course of cervical dystonia and patient satisfaction with long-term botulinum toxin A treatment

被引:68
作者
Skogseid, IM [1 ]
Kerty, E [1 ]
机构
[1] Univ Oslo, Rikshosp Univ Hosp, Dept Neurol, Oslo, Norway
关键词
cervical dystonia; Botulinum toxin A; disease course; long-term treatment; patient satisfaction;
D O I
10.1111/j.1468-1331.2004.01053.x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
In 78 patients with idiopathic cervical dystonia (CD), we studied the course of the disease and the patients' satisfaction with long-term botulinum toxin A (BTX) treatment (median 5.5 years, range 1.5-10). On a seven-point scale ranging from excellent to worsening, the effect of treatment was scored as excellent or good by 52% of patients and moderate by 33%. The independent scores of the treating neurologists were excellent or good in 65% and moderate in 27%, respectively, and correlated well with the patients' scores. The 'Global Burden of Disease', as expressed on Visual Analog Scales (VAS, 0-10) before and at evaluation of treatment, was reduced by a median of 4 in individual patients. By combining these outcome measures, 67% of the patients were characterized as having a good effect, and 33% an unsatisfactory effect. This outcome (good or unsatisfactory effect) was independent of the severity of head deviation or complexity pattern of CD prior to treatment, the delay from onset to start of BTX treatment, or the number of treatments. The complexity pattern remained stable during treatment in 64% of the patients, became less complex in 19%, whereas 17% of the patients developed more complex patterns.
引用
收藏
页码:163 / 170
页数:8
相关论文
共 28 条
[1]   BOTULINUM TOXIN TREATMENT IN SPASMODIC TORTICOLLIS [J].
BLACKIE, JD ;
LEES, AJ .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1990, 53 (08) :640-643
[2]  
Brashear A, 2000, MOVEMENT DISORD, V15, P150, DOI 10.1002/1531-8257(200001)15:1<150::AID-MDS1024>3.0.CO
[3]  
2-X
[4]   Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia [J].
Brin, MF ;
Lew, MF ;
Adler, CH ;
Comella, CL ;
Factor, SA ;
Jankovic, J ;
O'Brien, C ;
Murray, JJ ;
Wallace, JD ;
Willmer-Hulme, A ;
Koller, M .
NEUROLOGY, 1999, 53 (07) :1431-1438
[5]   The corticomotor representation of upper limb muscles in writer's cramp and changes following botulinum toxin injection [J].
Byrnes, ML ;
Thickbroom, GW ;
Wilson, SA ;
Sacco, P ;
Shipman, JM ;
Stell, R ;
Mastaglia, FL .
BRAIN, 1998, 121 :977-988
[6]   Teaching tape for the motor section of the Toronto western spasmodic torticollis scale [J].
Comella, CL ;
Stebbins, GT ;
Goetz, CG ;
Chmura, TA ;
Bressman, SB ;
Lang, AE .
MOVEMENT DISORDERS, 1997, 12 (04) :570-575
[7]  
Consky ES, 1994, Ther Botulinum Toxin, P211
[8]  
Coubes P, 2002, MOVEMENT DISORD, V17, pS6
[9]   Antibody-induced botulinum toxin therapy failure:: Can it be overcome by increased botulinum toxin doses? [J].
Dressler, D ;
Münchau, A ;
Bhatia, KP ;
Quinn, NP ;
Bigalke, H .
EUROPEAN NEUROLOGY, 2002, 47 (02) :118-121
[10]   Long-term botulinum toxin treatment of cervical dystonia - EMG changes in injected and noninjected muscles [J].
Erdal, J ;
Ostergaard, L ;
Fuglsang-Frederiksen, A ;
Werdelin, L ;
Dalager, T ;
Sjo, O ;
Regeur, L .
CLINICAL NEUROPHYSIOLOGY, 1999, 110 (09) :1650-1654